Skip to main content

Table 1 Characteristics of the 161 patients and distribution according to genotypes

From: Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy

 

Patients

 

   rs1800795

  

   rs8192284

 
 

no. (%)

C/C

C/G

G/G

 

A/A

A/C

C/C

 
   

No (%)

 

p

 

No (%)

 

p

Gender

    

0.4

   

0.8

Male

109 (68)

15 (14)

47 (43)

47 (43)

 

38 (35)

50 (46)

21 (13)

 

Female

52 (32)

4 (8)

21 (40)

27 (52)

 

20 (39)

23 (44)

9 (17)

 

Age (years)

    

0.06

   

0.1

> 75

43 (27)

9 (22)

17 (39)

17 (39)

 

20 (47)

14 (33)

9 (20)

 

< 75

118 (73)

10 (8)

51 (43)

57 (48)

 

38 (32)

59 (50)

21 (18)

 

ECOG PS

    

0.1

   

0.7

0

88 (55)

10 (11)

43 (49)

35 (40)

 

31.(35)

42 (48)

15 (17)

 

1

73 (45)

9 (12)

25 (34)

39 (54)

 

27 (37)

31 (43)

15 (20)

 

Weight loss

    

0.8

   

0.3

< 5%

106.(66)

13 (12)

46 (44)

47 (44)

 

37 (35)

52 (49)

17 (16)

 

> 5%

55 (34)

6 (11)

22 (40)

27 (49)

 

21 (38)

21 (38)

13 (24)

 

Anemia

    

0.05

   

0.3

Hb ≥10 gr/dl

113 (70)

11 (10)

43 (38)

59 (52)

 

43 (38)

52 (43)

18 (16)

 

Hb < 10 gr/dl

48 (30)

8 (17)

25 (52)

15(31)

 

15 (31)

21 (44)

12 (25)

 

Albumin

    

0.5

   

0.2

> 3.5 gr/dl

89 (55)

11 (3)

34 (38)

44 (49)

 

30 (34)

41 (36)

18 (20)

 

≤ 3.5gr/dl

72 (45)

8 (11)

34 (47)

30 (42)

 

28 (39)

32 (45)

12 (16)

 

CEA

    

0.5

   

0.4

< 5 ng/ml

96 (60)

10 (10)

44 (46)

42 (44)

 

36 (38)

45 (47)

15 (15)

 

≥ 5 ng/ml

65 (40)

9 (14)

24 (37)

32 (49)

 

22 (34)

28 (43)

15 (23)

 

Tumor grade

    

0.1

   

0.07

G 1-2

78 (49)

10 (12)

27 (35)

41 (53)

 

29 (37)

30 (38)

19 (25)

 

G 3

83 (51)

9 (11)

41 (49)

33 (40)

 

29 (35)

43 (52)

11 (13)

 

Histotype

    

0.9

   

0.1

Intestinal

95 (59)

12 (13)

40 (42)

43 (45)

 

31 (33)

42 (44)

22 (23)

 

Diffuse

66 (41)

7 (11)

28 (42)

31 (47)

 

27 (41)

31 (47)

8 (12)

 

First line RR

    

0.07

   

0.1

CR + PR

76 (47)

10 (13)

25 (33)

41 (54)

 

27 (36)

39 (51)

10 (13)

 

SD + PD

85 (53)

9 (10)

43 (51)

33 (39)

 

31 (36)

34 (40)

20 (24)

 

Liver mets

    

0.3

   

0.002

Absent

98 (60)

9 (9)

44 (45)

45 (46)

 

40 (41)

48 (49)

10 (10)

 

Present

63 (40)

10 (16)

24 (38)

29 (46)

 

18 (29)

25 (40)

20 (31)

 

LA/LR

    

0.7

   

0.6

Yes

90 (56)

10 (11)

36 (40)

44 (49)

 

35 (39)

40 (45)

15 (16)

 

No

71 (44)

9 (13)

32 (45)

30 (42)

 

23 (32)

33 (36)

15 (22)

 

Peritoneal mets

    

0.1

   

0.9

Absent

84 (52)

13 (15)

35 (42)

36 (43)

 

30 (36)

38 (45)

16 (19)

 

Present

77 (48)

6 (8)

33 (43)

38 (49)

 

28 (36)

35 (46)

14 (18)

 

Metastatic sites

    

0.6

   

0.4

1-2

112 (69)

12 (10)

50 (45)

50 (45)

 

44 (39)

48 (43)

20 (18)

 

> 2

49 (31)

7 (14)

18 (37)

24 (49)

 

14 (29)

25 (51)

10 (20)

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us